ONC - BeiGene, Ltd.

-

$undefined

N/A

(N/A)

BeiGene, Ltd. NASDAQ:ONC BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.

Location: No. 30 Science Park Road, Zhong-Guan-Cun Life Science Park, Beijing, BEIJING, China (Mainland) | Website: http://www.beigene.com/ | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

279.5B

Cash

19.04B

Avg Qtr Burn

-1.14B

Short % of Float

0.18%

Insider Ownership

19.41%

Institutional Own.

46.86%

Qtr Updated

09/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
BRUKINSA (zanubrutinib) Details
Blood cancer, Cancer, Small lymphocytic lymphoma , Chronic lymphocytic leukemia

Approved

Update

BRUKINSA + obinutuzumab Details
Cancer, Follicular lymphoma

Approved

Quarterly sales

Tislelizumab + chemo Details
Cancer, Gastroesophageal adenocarcinomas

Approved

Quarterly sales

TEVIMBRA (tislelizumab) Details
Cancer, Esophageal Squamous Cell Carcinoma

Approved

Quarterly sales

TEVIMBRA (tislelizumab) Details
Cancer, Esophageal Squamous Cell Carcinoma

PDUFA

Approval decision

BRUKINSA + tislelizumab Details
Cancer, Hepatocellular carcinoma

Phase 3

Data readout

Phase 3

Data readout

Phase 3

Data readout

Ociperlimab (Anti-TIGIT) Details
Non-small cell lung carcinoma, Cancer

Phase 3

Data readout

Tislelizumab Details
Cancer, Non-small cell lung carcinoma

Phase 3

Data readout

Ociperlimab (anti-TIGIT Ab) + tislelizumab Details
Non-small cell lung carcinoma, Small cell lung cancer, Cervical cancer, Esophageal Squamous Cell Carcinoma, Cancer

Phase 2

Data readout

Phase 1/2

Data readout

BGB-43395 Details
Cancer, HR+/HER2− breast cancer, Breast cancer

Phase 1

Data readout

BGB-16673 (BTK CDAC) Details
Cancer, B-cell malignancies

Phase 1

Data readout

BGB-A445 w/ tislelizumab Details
Renal cell carcinoma, Cancer, Bladder cancer, Melanoma

Phase 1

Update

Phase 1a

Data readout